SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
SEC Accession No. 0001193125-18-041084
Filing Date
2018-02-13
Accepted
2018-02-13 06:06:02
Documents
2
Group Members
LUMIRA CAPITAL GP, L.P.LUMIRA CAPITAL II (INTERNATIONAL), L.P.LUMIRA CAPITAL II L.PLUMIRA GP HOLDINGS CO.LUMIRA GP INC.

Document Format Files

Seq Description Document Type Size
1 SC 13G d507424dsc13g.htm SC 13G 116771
2 EX-99.1 d507424dex991.htm EX-99.1 9695
  Complete submission text file 0001193125-18-041084.txt   128343
Mailing Address P. O. BOX # 110341 RESEARCH TRIANGLE PARK NC 27709
Business Address 79 T.W. ALEXANDER DRIVE 4501 RESEARCH COMMONS, SUITE 100 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Subject) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-90214 | Film No.: 18598968
SIC: 2834 Pharmaceutical Preparations

Mailing Address 141 ADELAIDE STREET WEST SUITE 770 TORONTO A6 M5H 3L5
Business Address 141 ADELAIDE STREET WEST SUITE 770 TORONTO A6 M5H 3L5 416-213-4223
Lumira Capital Investment Management Inc. (Filed by) CIK: 0001702636 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: SC 13G